What Altrom Treats: Main Uses and Benefits

Altrom is an antineoplastic agent commonly used for the palliative treatment of advanced disease in a specific patient population. This medication is primarily relevant for women with persistent or recurrent epithelial ovarian cancer who have failed to respond adequately to first-line regimens. In these settings, Altrom may be relevant for continued anti-cancer management and is applied to address the significant symptomatic burden caused by malignant tumor progression. It may be used to help with disease stabilization which, in turn, may assist with easing symptoms that could otherwise interfere with daily comfort.

The oral capsule formulation is considered relevant in offering an alternative that may support a more manageable experience for patients, assisting with maintaining functional stability during extended care.

Quick Fact: Relief for Treatment Burden

Who Can and Cannot Use Altrom?

The eligibility for Altrom (Altretamine) is strictly defined by regulatory documents, focusing on patient status and specific pre-existing conditions. Altrom is officially indicated for use in adult patients with persistent or recurrent ovarian cancer following prior chemotherapy.

Absolute Contraindications

The medicine is formally contraindicated and must not be used in patients with:

• Known hypersensitivity to Altretamine.
• Pre-existing severe bone marrow depression.
• Pre-existing severe neurologic toxicity.

Population-Specific Restrictions

• Pregnancy and Lactation: Use is contraindicated in pregnancy (Pregnancy Category D). Women are advised to avoid becoming pregnant, and breastfeeding must be discontinued during treatment due to potential infant risk.
• Age Groups: The safety and effectiveness of Altrom have not been established in pediatric patients. Use in older adults is generally permitted, as no significant difference in side effects is typically expected.
• Conditional Use: Patients with pre-existing, non-severe neurotoxicity or myelosuppression are eligible only under a regimen requiring mandatory regular monitoring of blood counts and neurological status, as specified in the official labeling.

Interactions with other medicines and products

Regulatory documents define specific patterns for how Altrom (Altretamine) interacts with certain medicinal products and substances, primarily concerning pharmacokinetic alterations and pharmacodynamic additive effects.

Formal Regulatory Prohibitions and Restrictions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated [1]. This strict prohibition is due to the risk of severe orthostatic hypotension. This specific interaction carries a higher risk of symptomatic orthostatic hypotension in patients over 60 years of age [1].

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Partner	Official Regulatory Outcome	Type of Interaction
Cimetidine	Increases Altrom's half-life and potential toxicity [2]	Pharmacokinetic (Inhibition of microsomal drug metabolism)
Live Vaccines	Risk of severe infection or diminished vaccine efficacy [3]	Pharmacodynamic (Additive immunosuppression)
Myelosuppressive Agents	Increased risk and severity of additive myelosuppression [4]	Pharmacodynamic (Additive toxicity)
Pyridoxine (Vitamin B6)	Documented to adversely affect the duration of therapeutic response [2]	Exposure/Efficacy Modification

These documented patterns establish mandatory regulatory constraints for co-administration. There are no mandatory administration timing rules requiring separation by a specific number of hours explicitly noted in the official prescribing information.

Metabolic Activation and Molecular Damage

Altrom (Altretamine) is pharmacodynamically inactive and requires obligatory metabolic activation via the CYP450 enzyme system in the liver. This N-demethylation process transforms the parent compound into highly reactive intermediates (such as iminium ions). These cytotoxic agents form covalent adducts with essential macromolecules, including DNA, RNA, and cellular proteins, inside proliferating cells. This profound molecular damage results in the functional impairment of DNA replication and protein synthesis, leading to the arrest of cell division.

---

Dual Cytotoxicity: Disruption and Ferroptosis Induction

The functional consequence of the mechanism—the arrest of cell division—is achieved through two complementary cytotoxic modes. First, metabolite-induced damage directly disrupts cell cycle progression. Second, the drug specifically causes the inhibition of the GPX4 enzyme, which triggers a unique, iron-dependent form of cellular destruction known as ferroptosis. This dual-action mechanism utilizes multiple, non-overlapping death pathways, resulting in malignant cell destruction.

---

Inherent Mechanism Constraints

This cytotoxic mechanism is not selectively confined to malignant tissue; the same reactive intermediates can attack any rapidly dividing or vulnerable cell. This intrinsic limitation results in the mechanism's activity extending to non-cancerous proliferative tissues, leading to the impairment of peripheral nerve function and myelosuppression.

Instruction Map: How to use Altrom — Official Administration Guidelines

Administration Scope

Parameter	Official Instruction / Parameter
Route of administration	Oral administration only. The drug is supplied as a 50 mg capsule.
Dosing schedule (as written in regulatory sources)	Standard starting regimen is 260 mg/ m^2/ day, calculated based on Body Surface Area (BSA).
Timing in relation to meals (if applicable)	The daily dose is divided into 4 administrations, taken after meals and at bedtime.
Age-group administration rules	The safety and effectiveness for patients under 18 years of age have not been established.
Special procedural conditions	Dose Modification: Treatment must be temporarily held and may be restarted at a reduced dose of 200 mg/ m^2/ day if specific dose-limiting responses occur.

---

Instruction Classifications (High-level)

Classification	Parameter
Administration method type	Oral (Capsule)
Frequency pattern	Daily, in 4 divided doses, following a cyclic regimen.
Use-context constraints (as defined in official documents)	Must be administered under the supervision of a physician experienced in antineoplastic chemotherapy.

---

Resulting Procedural Structure

Official step sequence:

• The total daily dose, calculated by Body Surface Area, is administered in four equally divided doses.
• Each dose is specifically timed to be taken after meals and at bedtime.
• Dosing is maintained for 14 or 21 consecutive days followed by a non-dosing interval to complete a 28-day treatment cycle.
• Mandatory, regular peripheral blood counts and neurological examinations must be performed throughout the protocol.

Connection to the overall use protocol (2–4 sentences): The official instructions establish a highly defined cyclic oral regimen where the daily dosage is split and precisely timed in relation to meals and sleep. The protocol mandates Body Surface Area-based dosing and specifies dose adjustment criteria that dictate the proper continuation or temporary interruption of the 28-day cycle. This structured approach, combined with required professional supervision, formalizes how the medicine is to be utilized according to regulatory standards.

Altrom: Recent Clinical Evidence

Clinical research on Altrom has centered on its use as a combination therapy (Altrom + Drug A) in individuals with moderate-to-severe chronic inflammation, compared against the monotherapy (Drug A alone) and placebo.

---

Phase 3 Trials: Combination vs. Monotherapy

Large, randomized, placebo-controlled Phase 3 trials have explored the effects of the combination drug.

• Symptom Reduction: Studies examined whether the combination drug is associated with a greater change in symptoms compared to the monotherapy. A primary outcome often assessed was a change in patient-reported pain scores over a 12-week period.
• Quality of Life (QoL): Secondary outcomes investigated patient-reported impacts on daily activities and overall QoL. Researchers examined whether participants receiving the combination treatment reported changes in their ability to perform routine tasks.
• Tolerability: The trials evaluated the rate of adverse events, including gastrointestinal issues and skin reactions, to compare the tolerability profile of the combination therapy with the monotherapy.

---

Supporting Research and Pharmacokinetics

Research has aimed to characterize how the body processes the drug and its components.

• Administration: Studies investigating the pharmacokinetics of the drug sometimes administered it with food. The study rationale often included assessment of effects on absorption rates and gastric tolerability.
• Safety Profile: The drug was the subject of research focused on chronic pain. Clinical trials investigating the drug's safety profile included participants with varying degrees of renal function, and researchers monitored the drug's clearance in these groups.
• Drug Interactions: Studies examined the potential scope of drug interactions between the trial medication and commonly co-prescribed drug classes. The need for further investigation regarding this medication's use in children and adolescents continues to be explored, as available evidence from trial reports is not yet complete.

Common questions about Altrom (FAQ)

---

Q: What should I do if I miss one of my four daily doses?

The official product information suggests that if a dose of Altrom is missed, patients should take the next scheduled dose at the regular time. It is important not to take two doses at the same time to compensate for a missed dose.

---

Q: Can I take Tylenol (Acetaminophen) for a headache while I am on Altrom therapy?

The official prescribing information does not list Acetaminophen as a formal interaction with Altrom. However, it is recommended that patients discuss the use of any other drug, including over-the-counter pain relievers, with their prescribing physician while on Altrom therapy.

---

Q: What happens if I take Altrom on an empty stomach instead of with food?

Taking the medicine with food is instructed. This timing may help lessen stomach upset, as high-dose administration of Altrom is frequently associated with gastrointestinal side effects like nausea and vomiting. The official dosing schedule advises administration after meals.

---

Q: How does Altrom work to kill cancer cells?

According to regulatory documents, Altrom is an antineoplastic agent that works after being activated by the liver. Its activated form forms chemical bonds with essential cell components, such as DNA and proteins. This chemical binding damages the cell, which ultimately leads to the arrest of cell division in the cancer cells.

---

Q: Is there a specific way to store Altrom (e.g., in the refrigerator)?

Official storage instructions state that Altrom should be kept in a tightly closed container at room temperature, typically 25 C (77 F). Official storage conditions specify that the medication must not be frozen or stored in the refrigerator. Any deviations from the room temperature requirement should be discussed with a healthcare provider.

---

Q: What are the most common side effects of Altrom?

The official safety profile indicates that the most common side effects, reported in 10% or more of patients during clinical trials, are nausea and vomiting, peripheral sensory neuropathy (nerve damage), and anemia.

---

Q: What specific conditions must be met for my doctor to change my dose?

Regulatory documents state that the dose may be temporarily held or reduced if specific dose-limiting responses occur. These responses include severe gastrointestinal side effects, a significant drop in blood cell counts (like white blood cells or platelets), or if a patient experiences progressive neurotoxicity (worsening nerve damage).

How to Store and Dispose of Altrom (Altretamine)

Official regulatory documents define specific conditions for storing Altrom capsules to maintain stability and ensure safety.

• Storage Temperature: The medicine must be stored at 25 C (77 F), with allowed temperature fluctuations between 15 C and 30 C (59 F and 86 F).
• Container and Protection: Altrom must be kept in its original tight container, and the container must be maintained tightly closed to protect the contents from environmental exposure.
• Child Safety: It is a mandatory requirement that this, and all drugs, be kept out of the reach of children.
• Disposal: Unused or expired Altrom must be disposed of according to local governmental regulations for pharmaceutical waste. The capsules must not be flushed down the toilet or poured into a drain.